SEC freezes Nasdaq's Bitcoin options approval following CME legal challenge
The U.S. SEC has frozen its approval for Nasdaq's cash-settled bitcoin index options (QBTC) following a legal challenge from rival exchange CME Group. CME argues that bitcoin is a commodity, placing such products under the exclusive jurisdiction of the CFTC, not the SEC, and that the approval could set a dangerous precedent. The product remains suspended pending a full commission review, with public comments due by August 24.
SEC approval freeze
▪The SEC has invited interested parties to submit statements supporting or opposing the approval by August 24.
▪The U.S. Securities and Exchange Commission (SEC) has paused its approval for Nasdaq to list cash-settled bitcoin index options.
▪The SEC's pause is to reconsider its decision following a legal challenge from CME Group.
CME jurisdictional challenge
▪CME Group contends that options tied to bitcoin's value fall under the exclusive jurisdiction of the Commodity Futures Trading Commission (CFTC).
▪CME's petition warned that the SEC's approval could set a precedent for securities exchanges to list derivatives on other commodities.
▪CME Group challenged the SEC's approval in June, arguing that bitcoin is a commodity.
CFTC versus SEC authority
▪CME argued that regulatory exemptions cannot be used to transfer a product from one regulator's jurisdiction to another.
▪If CME Group's argument is correct, the SEC would lack the authority to approve the QBTC product.
▪CME Group already operates regulated bitcoin futures and options markets under the CFTC's framework.
QBTC product structure
▪The QBTC product required exemptions from the CFTC before it could launch, even with the SEC's initial approval.
▪Nasdaq's proposed QBTC contracts would use CME CF benchmarks for both their underlying index and final settlement price.
▪The proposed Nasdaq product, under the ticker QBTC, received conditional approval from the SEC in May.
Story comments
Loading comments…